Navigation Links
AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
Date:5/13/2008

oliferation gene signatures are essentially redundant, and they do not go beyond ER/PR in determining the likelihood of responding to endocrine therapy," said Antonius Schuh, PhD, chief executive officer of AviaraDx, Inc. "H/I and MGI together provide a more complete diagnostic picture that should help clinicians make more appropriate treatment decisions for their breast cancer patients."

"This is the first analysis linking H/I to our new, five-gene tumor grading index, MGI," said Mark Erlander, PhD, chief scientific officer for AviaraDx, Inc. "For patients whose tumors have high MGI values, it is important to measure H/I in order to determine likely benefit from endocrine therapy within the setting of a highly proliferating tumor."

The authors conclude that these two markers together should enable oncologists to identify a large subgroup of women with low risk of recurrence who may be spared from toxic chemotherapy regimens. In addition, they may also identify a significant population of patients for whom intensive chemotherapy regimens or new therapeutic agents should be considered.

"As molecular diagnostics enable the personalization of patient care, we will help patients and clinicians determine appropriate therapies and avoid both over- and under-treatment," added Schuh.

Approximately 100,000 women present with ER-positive, node-negative breast cancer in the United States every year. The data included in this month's Clinical Cancer Research publication show that the combination of Aviara MGI and Aviara H/I provides objective information to better assess both recurrence risk and potential for response to systemic therapies in these early stage breast cancer patients. The combination of these two biomarkers is now commercially available as the Aviara Breast Cancer Index(SM).

About AviaraDx, Inc.

AviaraDx discovers, develops, and commercializes new molecular diagnostic tests in oncology, enabling physicians to personalize
'/>"/>

SOURCE AviaraDx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
2. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
3. FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
4. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
5. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
6. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
7. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
8. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
9. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
10. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
11. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)... , Sept. 16, 2014 Surgeons at ... describe in a case report the first successful use ... a 13- year-old boy with failing Fontan circulation to ... he was 3 years old, the patient received a ... as functional single ventricle. "The Fontan operation is the ...
(Date:9/16/2014)... Research and Markets has ... Devices Industry Report 2014" report to their ... Industry Report 2014 is a professional and in-depth ... laparoscopic devices. The report provides a ... applications and industry chain structure. The laparoscopic devices ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3Global Laparoscopy Devices Industry Report 2014 2
... 23, 2011 The U.S. Food and Drug Administration ... active ulcerative colitis (UC) in children older than 6 ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... induces and maintains clinical remission in these patients. ...
... ANN ARBOR, Mich., Sept. 23, 2011 Adapting adult medical ... often problematic practice across U.S. hospitals. At the ... and researchers who care for children have been leading the ... test medical devices and curb problems that come from using ...
Cached Medicine Technology:FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years 2FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years 3University of Michigan Pediatric Device Inventors Awarded Funds to Design Child-Specific Medical Devices 2University of Michigan Pediatric Device Inventors Awarded Funds to Design Child-Specific Medical Devices 3University of Michigan Pediatric Device Inventors Awarded Funds to Design Child-Specific Medical Devices 4
(Date:9/16/2014)... Centre, NY (PRWEB) September 16, 2014 ... product manufactured by Johnson & Johnson subsidiary Ethicon concluded ... of plaintiff Jo Huskey and awarding her $3.27 million ... According to the Reuters report, “jurors found Ethicon liable ... and their doctors that users were at risk from ...
(Date:9/16/2014)... Advanced Fertility Center of Texas’ Dr. ... as one of the Top Doctors of 2014. The ... metropolitan magazine serving the Houston area. They award esteemed ... their outstanding services. This accomplishment will be included in ... — a special publication listing all the winners of ...
(Date:9/16/2014)... September 16, 2014 Duke’s Chowder House ... Rebls and Gratafy for a fun evening ... hub is firmly cemented. With the growth of companies in these ... for people who work in tech and at startups to connect ... Gratafy are happy to host events for their peers to meet ...
(Date:9/16/2014)... Treatment with endocrine therapy and radiation therapy as ... of care for women with hormone-receptor positive (HR+) ... at Fox Chase Cancer Center, however, shows that ... populations with the disease. , The results, ... Society for Radiation Oncology,s 56th Annual Meeting on ...
(Date:9/16/2014)... 16, 2014 This year’s theme is ... Sustainable company Glen Mills, Pennsylvania, September 15, 2014- Holganix, ... of the fastest growing companies in the country, produces ... shrub, and tree health-care by naturally decreasing disease and ... Today it announced that it will hold its third ...
Breaking Medicine News(10 mins):Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 3Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2
... who don,t metabolize drug well, , FRIDAY, March 12 (HealthDay ... "black box" warning on its label, alerting patients and doctors ... officials said Friday. , Patients with a certain genetic variation ... puts them at risk for heart attack and stroke, the ...
... with a known sex offender is beginning to settle in as a dark, dark corner of the landscape of life. Slowly we are taking up our routines again, changed by ... ... ... ...
... released the following statement.  , ... , , ... ... "We applaud the steps taken by the Congressional Black Caucus and the White House to meet to discuss the ...
... , ... , ... ... ST. LOUIS , March 12 More than 200 Teamsters and religious leaders held a rally and prayer vigil at Ascension ...
... Award Presented to Joel A. Gingras, Jr. Memorial Fund , ... , , ... ... CHICAGO , March 12 The American Brain Tumor Association (ABTA) presented its first ...
... profitable and industry-leading corporation, LIMU, based in Florida , today announced a brand transformation for 2010.   With ... upcoming international convention March 19 – 20, 2010 in Dallas, Texas . , ... ... , ...
Cached Medicine News:Health News:Plavix Less Effective in Some Patients 2Health News:Plavix Less Effective in Some Patients 3Health News:TypeAMom.net on Keeping Daughters Safe From Predators 2Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 2Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 3Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 4Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 5Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 6Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 7Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 8Health News:American Brain Tumor Association Recognizes Philadelphia Family Foundation With Annual Award 2Health News:American Brain Tumor Association Recognizes Philadelphia Family Foundation With Annual Award 3Health News:LIMU Accelerates Growth Era With Brand Transformation 2Health News:LIMU Accelerates Growth Era With Brand Transformation 3
... The RapidPCP test is an immunochromatography ... It is,designed for qualitative determination of ... cut-off level of 25 ng/mL. This ... the point of care location,and is ...
... Rapid Opiate II Rapid Opiates is an ... is designed for qualitative determination of Opiates ... presence of morphine in human urine above ... This assay has not been evaluated in ...
... All of DOA Panel ... one step in vitro test. ... of drug substances in human ... not,been evaluated in the point ...
... an immunochromatography based one step in vitro ... THC and its metabolites in human urine,specimens. ... urine above a cut-off,level of 50 ng/mL ... been evaluated in the point of care,location ...
Medicine Products: